Mendeley出力
＜学術雑誌論文＞
くすりで肺がんを治す―過去・現在・未来
| 作成者 | |
|---|---|
| 本文言語 | |
| 出版者 | |
| 発行日 | |
| 収録物名 | |
| 巻 | |
| 号 | |
| 開始ページ | |
| 終了ページ | |
| 出版タイプ | |
| アクセス権 | |
| JaLC DOI | |
| 概要 | Development of drug therapy for lung cancer originates in cytotoxic drugs. Following the report which indicate usefulness of cyclophosphamide for lung cancer, many cytotoxic drugs including cisplatin ...and taxanes were developed in the last century. However, their efficacy was modest and cure of metastatic lung cancer used to be an impossible dream. The paradigm shifted in 21st century due to a development of molecular targeted therapy followed by discovery of driver gene mutation. Today, selection of appropriate drug for patient with non-small cell lung cancer (NSCLC) is based on biomarker test including driver gene mutation, resulting in enhancement of therapeutic effects and avoidance of ineffective drugs. In addition, immune check point inhibitor was known to bring patientsʼ long term survival. Before cisplatin, 5-year survival rate of metastatic NSCLC used to be less than 1%. While, our present goal is to achieve longer than 50%. The era to cure lung cancer with drug therapy is just around the corner.続きを見る |
| 目次 | 災い転じて福となす：抗癌薬の事始め 毒と薬の境界線：細胞障害性抗癌薬の発展 環境ではない，アイデアだ：ドライバー遺伝子の発見と肺癌薬物療法のバラダイムシフト 我々はどこまで来たのか？ |
詳細
| PISSN | |
|---|---|
| NCID | |
| レコードID | |
| 査読有無 | |
| 主題 | |
| タイプ | |
| 登録日 | 2019.12.18 |
| 更新日 | 2021.03.03 |